Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6227639 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6229410 | 0.94 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6229402 | 0.94 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6229104 | 0.92 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6229095 | 0.92 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6231821 | 0.92 | MEN1 (0.44) | ALDH1A1LMNAGAAMEN1KMT2A | |
| SCHEMBL6231830 | 0.92 | MEN1 (0.44) | ALDH1A1LMNAGAAMEN1KMT2A | |
| Mandipropamid SCHEMBL675075 | 0.90 | GAA (0.52) | ALDH1A1SMN1; SMN2LMNAGAAMEN1 | |
| Mandipropamid SCHEMBL29379242 | 0.90 | GAA (0.52) | ALDH1A1SMN1; SMN2LMNAGAAMEN1 | |
| Mandipropamid SCHEMBL22338 | 0.90 | GAA (0.52) | ALDH1A1SMN1; SMN2LMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444197-B1 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-03-30 | — | — | EP | claimed |
| US-20050026785-A1 | Novel phenyl-propargylether derivatives | SYNGENTA CROP PROTECTION, INC. | 2005-02-03 | — | — | US | claimed |
| EP-1444197-A1 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | Syngenta Participations AG (CH) | 2004-08-11 | — | — | EP | claimed |
| WO-2003041728-A9 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-22 | — | — | WO | claimed |
| WO-2003041728-A1 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-05-22 | — | — | WO | claimed |
| EP-1444197-B1 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20050026785-A1 | Novel phenyl-propargylether derivatives | SYNGENTA CROP PROTECTION, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1444197-A1 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | Syngenta Participations AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041728-A9 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003041728-A1 | NOVEL PHENYL-PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026785-A1 | Novel phenyl-propargylether derivatives | OR10J3, PRXL2A, OSR1 | ALDH1A1 1556/4885SMN1; SMN2 4752/4885LMNA 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.